News | Cardiovascular Clinical Studies | January 03, 2023

Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation at the 2023 AF Symposium

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”

January 3, 2023 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston. This abstract – including full study results - will be presented on Friday, February 3, 2023.

The AcQForce Flutter clinical study was submitted to the FDA as part of Acutus’ PMA submission for the AcQBlate Force Sensing Ablation Catheter, the only force-sensing ablation catheter with a gold tip electrode, and System. The irrigated gold tip ablation catheter has 4x thermal conductivity compared to platinum catheters, which allows for significantly more energy delivery at a lower temperature and requires less saline flow.1 This is the first PMA submission by Acutus and the first time the company is presenting at a Late-Breaking Clinical Trials session.

For more information: https://acutusmedical.com

Reference

1. Linhart M. et al., Superiority of Gold Compared to Platinum Tip Irrigated Catheter Ablation of the Pulmonary Veins and the Cavotricuspid Isthmus: A Randomized Study Comparing Tip Temperatures and Cooling Flow Requirements. J Cardiovasc Electrophysiol. 2012 Jul; 23(7): 717–21


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now